Molecular and Clinical Analyses of 111 Patients with Bilateral Anterior-Segment Dysgenesis/Aniridia and Microphthalmia/Anophthalmia.

Objective: To clarify the molecular and clinical characteristics of anterior-segment dysgenesis (ASD)/aniridia and microphthalmia/anophthalmia caused by monogenic variants. Design: Clinical and genetic analyses of a large cohort of patients with bilateral ocular lesions. Participants: A total of 111 patients and their family members were recruited through a multicenter collaborative study in Japan. Methods: Next-generation sequencing using custom-designed panels for 11 and 12 major causative genes for ASD/aniridia and microphthalmia/anophthalmia, respectively. We analyzed the clinical information of patients with pathogenic or likely pathogenic variants. Main Outcome Measures: Collated genetic results and clinical data. Results: We achieved genetic diagnosis rates of 50.0% for ASD/aniridia and 37.5% for microphthalmia/anophthalmia. We identified 11 previously unreported variants. De novo variants in the Conclusions: This study provides evidence that targeted gene panel approaches are useful for the clinical diagnosis of ASD/aniridia and microphthalmia/anophthalmia. Our data clarified the mutation spectrum and phenotypic characteristics of these disorders caused by monogenic variants. This study confirmed that various phenotypes classified as ASD, such as Peters anomaly and Axenfeld anomaly, constitute a group of disorders on the same spectrum, may overlap with aniridia, and exhibit genetic heterogeneity. The findings, which demonstrate an association between genotypes and complications, are expected to contribute to better management and care for children with these rare intractable eye diseases. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.